Cancer and the older patient
Accurate data on the frequency and severity of toxic effects from anticancer agents is essential if patients and their doctors are to make informed decisions about what is euphemistically called the risk—benefit ratio of cancer treatment.
Throughout my practising lifetime, I have discussed potential side effects of the various cytotoxic chemotherapy protocols with patients. To facilitate such discussions, I have always used published data from high-quality clinical trials.
Too often, I watched the people I treated suffer more frequent, and more severe, adverse effects than